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Background and Aim:T cell expression of PD1 and inhibition ofT effector cells by Foxp3+-
T regulatory cells are among the most powerful mechanisms for achieving a balanced
immune response. Our aim was to investigate, how liver FOXP3 and PD1/PDL1 expres-
sion is regulated in chronic HBV hepatitis (CHB) on maintained long-term remission in
comparison with active disease, and whether they are correlated to the expression of
pro- and anti-inflammatory cytokines and apoptosis mediators, along with the degree of
histological inflammation and markers of T cell effector restoration.
Methods: Fifty-three HBeAg-negative CHB patients with both active (30) and completely
remitted disease on long-term antiviral treatment (23) and four controls (submitted to liver
biopsy due to a mild increase of aminotransferases but without liver necroinflammatory
and architecture changes) were enrolled in the study. Liver mRNA levels of immunoregula-
tory genes (FOXP3, IL10,TGFB1, and those of PD1/PDL1/PDL2 pathway), major apoptosis
mediators (FAS, FASL, TNFA, TRAIL), cytokines of effector T cell restoration (IL2, IFNG),
and those of IL1B, CD4, and CD8, were evaluated by quantitative real-time reverse-
transcriptase PCR and were correlated with each other, along with the intensity of liver
inflammation and fibrosis staging. The expression and localization of FOXP3, PD1, PDL1,
CD4, and CD8 were also assessed by immunohistochemistry.
Results: The expression of FOXP3, IL10, TGFB1, PD1, PDL1, FASL, and CD8 was signifi-
cantly down-regulated in the remission state. In contrast, liver expression of IL2 and IFNG,
along with CD4, IL1B,TNFA, and FAS did not change significantly. Moreover, FOXP3, PD1,
PDL1, and CD8 transcripts were positively correlated to the intensity of liver inflammation.
Conclusion: Our data indicate that in the CHB disease model, the immunosuppressive
liver environment is down-regulated in the maintained on-treatment long-term remission
state and correlates with the intensity of liver inflammation, but not liverT cell restoration.
Keywords: chronic HBV hepatitis, regulatoryT cells, FOXP3, PD1/PDL1, FAS/FASL, inflammation
INTRODUCTION
The most important process for the immune control and inacti-
vation of hepatitis B virus (HBV) infection is a robust immune
response, either spontaneous or treatment induced (1, 2). How-
ever, in chronic active infection (chronic HBV hepatitis, CHB), the
impaired and/or unbalanced T cell responses are unable to control
viral replication but are sufficient to cause chronic liver damage.
The latter is initially dependent on viral antigens expressed on
hepatocytes and anti-HBV specific CD8+-cytotoxic T-lymphocyte
(CTL) responses; afterward, the chronic liver damage is amplified
by non-specific liver infiltrating cells and CD4+-T cell interaction
pathways (1, 2).
Among the most powerful mechanisms for achieving a bal-
anced immune response are the expression of programed death
1 (PD1) molecule by T cells (3) and the inhibition of effector
T cells (Teffs) by CD4+-T regulatory cells (Tregs) (4). Models
of viral infection have indicated that the interaction between the
inhibitory receptor PD1, expressed in high levels on lymphocytes,
and its ligands program cell death 1 ligand (PDL)-1 and PDL2,
plays a critical role in T cell exhaustion by inducing T cell inacti-
vation (3, 5). In CHB patients, high PD1 levels are expressed by
virus-specific T cells and improvement of the T cell function has
been obtained in vitro by inhibition of the PD1/PDL1 interaction
(3, 5). Particularly, the PD1/PDL1 blockade increased CD8+ T
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cell proliferation, as well as the production of interferon-gamma
(IFN-γ) and interleukin (IL)-2 production by intrahepatic lym-
phocytes, inducing variable levels of functional T cell restoration
both in the liver and in peripheral blood, with a better functional
improvement among intrahepatic T cells (5). Moreover, Tregs are
important mediators of immune suppression and their presence
prevents reactions against self by inducing regulatory signals to
antigen presenting cells (APCs) and/or Teffs (6, 7). Their ablation
increases the risk of autoimmunity (8) whilst,on the contrary, their
signals could also affect non-autoreactive clones, leading to inhi-
bition of antineoplastic, antimicrobial, antiparasitic, and antiviral
immune responses (7, 9).
Previous studies have indicated that patients with chronic
viral hepatitis display increased numbers of Tregs (both nat-
ural and inducible) in peripheral blood (10–12) or liver (13,
14), which, in turn, exert a suppressive function against spe-
cific HBV- or hepatitis C virus (HCV)-Teffs in vitro (10–14).
Interestingly, Aoki et al. reported that the loss of natural Tregs
(characterized by the constitutive expression of FOXP3 gene)
induces fatal autoimmune hepatitis (AIH) in neonatal thymec-
tomized (NTx)-PD1−/− mice, due to migration of dysregulated
follicular T helper (Tfh) cells from the spleen (15). In this con-
text, we have recently demonstrated that the FOXP3 expression
in liver is positively correlated with the intensity of liver inflam-
mation along with a specific pattern of mRNA expression of the
apoptosis mediators FAS, FASL, and TRAIL, irrespective of the
cause of tissue damage (viral, toxic, autoimmunity), suggesting
that might represent a bystander effect and not a causative event
of chronic inflammation (16). Considering also that our findings
were in line with the attractive view of Zheng and Rudensky (7)
claiming that Tregs “have a vital role in preventing autoimmu-
nity and pathology inflicted by uncontrolled immune responses
to infections,” we suggested a comprehensive protective model
of Tregs to prevent catastrophic pathology on apoptosis-induced
inflammation (16).
The aim of this study was to explore whether the long-term
antiviral treatment in patients with HBeAg-negative CHB affects
the abovementioned model, investigating also another impor-
tant apoptosis pathway implicated in Teffs dysfunction in liver,
namely the PD1/PDL1. Thus, the expressions of FOXP3, charac-
terizing mainly nTregs (7), as well as those of IL10 (encodes IL-10)
and TGFB1 (encodes TGF-β1), characterizing type I (Tr1) and
T helper type 3 (Th3) inducible Tregs (iTregs) (17), respectively,
were examined at the same time with the PD1/PDL1/PDL2 path-
way, in relation to the expression of major apoptosis mediators,
namely TNFRSF6/FAS (encodes FAS), TNFSF6/FASL (encodes
FASL), TNFA (encodes TNF-α), and TNFSF10/TRAIL (encodes
tumor necrosis factor related apoptosis inducing ligand, TRAIL).
Furthermore, the expression of the inflammatory cytokine IL-1β
(encoded by IL1B gene) and cytokines of the immune effec-
tor T cell restoration (IL-2, encoded by IL2 gene and IFN-γ,
encoded by IFNG gene), together with the expression of CD4
and CD8 were explored. Our data provide clear evidence that in
CHB HBeAg-negative disease model, the immunosuppressive liver
environment is down-regulated in the maintained on-treatment
long-term remission state and correlates with the intensity of liver
inflammation, but not with liver T cell restoration.
MATERIALS AND METHODS
PATIENTS
Liver biopsy specimens obtained from 53 patients with CHB
were examined; 30 were newly diagnosed and were evaluated
before any treatment and 23 were on maintained continuous
antiviral treatment response and remission for at least 240 weeks
(5 years) with entecavir. Nine out of 30 newly diagnosed CHB
patients were derived from a previous study of our group (16),
since their genetic material was also available for the analysis
of all genes included in this study. Considering that in Eastern
Mediterranean area the HBV genotype D and HBeAg-negative
serological form of CHB prevails (about 90% of affected Greek
patients) (18), all the enrolled patients had the abovementioned
HBV genotype. The treatment efficacy at year 5 included the
biochemical response based on normalized ALT levels, and the
complete virologic response defined as serum HBV DNA <169
copies/mL (29 IU/mL), namely the lower limit of quantification
of the COBAS TaqMan assay (Roche Molecular Systems). None
of the patients presented with co-infection with other hepati-
tis viruses (types A, C, D, and E) or with HIV, or was receiving
any other immunomodulatory treatment during the last 6 months
prior to liver sampling. HBV DNA quantification was performed
with the bDNA assay V2.0 (Bayer, Siemens). A summary of the
demographic, clinicopathologic, and serologic data of the analyzed
CHB patients is presented in Table 1.
Each liver biopsy specimen was separated into two parts. One
of them was immediately fixed in 10% formalin solution for diag-
nostic histological examination, and the other was snap frozen and
stored at −80°C until further use. Formalin-embedded sections
Table 1 | Clinicopathological and serological data of the patients of
the study.
Chronic HBV
hepatitis at
diagnosis
Chronic HBV hepatitis
on sustained
remission
No 30 23
Sex (M/F)a 13/17 18/5
Age (median, range) 47, 21–64 52, 23–73
ASTb (U/µL), (median, range) 43, 17–1969 24, 15–51
ALTc (U/µL), (median, range) 54, 15–1478 27, 15–49
Inflammation graded
I-0d 0 1
I-1d 8 18
I-2d 14 4
I-3d 6 0
I-4d 2 0
Fibrosis (median, range)d 2.5, 0–6 2.0, 0–4
HAI score (median, range) 5.5, 1–15 2.0, 0–7
Viral load (median, range) 105 Meq/mL
(0.007–521)
0 Meq/mL
(0–0.008)
aM, male; F, female; bAST, aspartate aminotransferase; cALT, alanine aminotrans-
ferase; d inflammation grade (I-0: without inflammation, I-1: minimal, I-2: mild, I-3:
moderate, and I-4: marked) and fibrosis stage were assessed as presented in the
section of Material and Methods.
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were stained by hematoxylin-eosin and Masson’s trichrome. Two
independent pathologists assessed and scored each biopsy and
any discrepancy was further evaluated by an expert pathologist.
The samples were blinded to the timing of biopsy and treatment
assignment. Core length and number of portal tracts were taken
into account to determine adequacy of biopsy specimens. Biopsy
slides were graded and staged with the Ishak scoring system (19,
20). Furthermore, according to the intensity of liver inflammation
in the biopsy specimens, the patients were classified as I-0 (no
inflammation), I-1 [minimal inflammation, histological activity
index (HAI) score 1–4], I-2 (mild inflammation, HAI score 5–8),
I-3 (moderate inflammation, HAI score 9–12), and I-4 (marked
inflammation, HAI score 13–18) and the latter classification was
used in the statistical analysis (Table 1).
Informed consent was obtained by all participants and the study
was approved by the Institutional Review Board. One of the chal-
lenges experienced in this study was the obtaining of informed
consent from patients undergoing liver biopsy without a clear
clinical need (patients on maintained remission), considering that
they had complete virologic suppression at year 5 on continuous
antiviral treatment.
QUANTITATIVE REAL-TIME REVERSE-TRANSCRIPTASE PCR
Total RNA was isolated from stored liver samples after homoge-
nization, using TRI (Life Technologies, Invitrogen, Thessaloniki,
Greece), according to the manufacturer’s instructions. Comple-
mentary DNA (cDNA) was reversed transcribed from 1µg of
the total RNA, using a random 6-mer oligonucleotide primer
(50 pmol/µL) (Roche, USA) and M-MLV reverse transcriptase
(Invitrogen), according to the manufacturer’s instructions.
The mRNA levels of 15 genes, namely FOXP3, IL10, TGFB1,
TNFRSF6/FAS, TNFSF6/FASL, TNFSF10/TRAIL, PD1/PDCD1
(encodes PD1), PDL1/PDCD1LG1 (encodes PDL1), PDL2/
PDCD1LG2 (encodes PDL2), IL2, TNFA, IFNG, IL1B, CD4
(encodes CD4), and CD8a (encodes CD8) were determined in
a Quantitative real-time reverse-transcriptase PCR (qRT-PCR)
using SYBR-Green PCR Supermix (Invitrogen, UK), in the auto-
mated thermocycler RotorGene 6000 (Corbett Life Science, Syd-
ney, Australia). The B2M gene was used as an internal control
for sample normalization (reference gene). An 1/20 aliquot of
the cDNA reaction product was used in duplicate qRT-PCR
reactions and all measurements were averaged. Primers for the
amplification of the genes FOXP3, IL10, TGFB1, TNFRSF6/FAS,
TNFSF6/FASL, TNFSF10/TRAIL, IL2, TNFA, IL1B, PD1/PDCD1,
and IFNG were commercially obtained by Qiagen (Valencia, CA,
USA). The primers for the amplification of PDL1/PDCD1LG1,
PDL2/PDCD1LG2, CD4, and CD8a were designed with the aid of
the Oligo 6.0 software (NBI, Plymouth, MN, USA) and are pre-
sented in Table 2. Thermocycling conditions of the analyzed genes
are also presented in Table 2. The efficiency of each qRT-PCR reac-
tion ranged between 0.9 and 1.05. Relative quantification and cal-
culation of the range of confidence were performed using the com-
parative∆∆CT method, as described (21). The relative expression
of each gene is presented as a multiple of the respective gene expres-
sion in a sample of a patient who underwent liver biopsy due to a
mild increase of aminotransferases but without liver architecture
changes (histology negative for disease; “healthy” control).
IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for FOXP3, PD1, and PDL1 proteins,
as well as CD4 and CD8 antigens, were performed on 4µm-thick
paraffin sections of 15 newly diagnosed before any treatment and
12 on maintained continuous antiviral treatment response and
remission biopsy specimens. The primary monoclonal antibodies
utilized for immunohistochemistry and their dilutions are shown
in Table 3. All immunohistochemical stains except for PD1 were
performed in an automated Bond system (Menarini), with the use
of the Bond polymer refine detection kit. Stains for PD1 were per-
formed in a DAKO autostainer, with the use of an Envision Flex
Plus kit.
STATISTICAL ANALYSIS
For basic statistical calculations, all gene expression levels were
treated as continuous variables. Differences of gene expression
between different disease statuses were analyzed by the non-
parametric Mann–Whitney U test. The association of the above
parameters with inflammation and fibrosis staging was tested
with the Kruskal–Wallis H test. Spearman’s rank correlation
coefficient was used to estimate the correlations of the expres-
sion among the aforementioned genes, as well as the correla-
tions of gene expressions with aminotransferases levels or viral
load. Mann–Whitney U test, Kruskal–Wallis H test, and Spear-
man’s correlation analyses were appropriately performed by the
using of SPSS (version 18.0, Chicago, IL, USA). Differences were
considered statistically significant when the p-value (two sided)
was <0.05.
RESULTS
GENE AND PROTEIN EXPRESSION IN RELATION TO CHB STATUS
As shown in Figure 1, patients maintained on-treatment at 5 years
remission (virologic, biochemical, and histochemical) of CHB
had significantly decreased mRNA levels of FOXP3, IL10, TGFB1,
TNFSF6/FASL,PD1/PDCD1,PDL1/PDCD1LG1, and CD8a, as well
as significantly increased levels of TNFSF10/TRAIL, as compared
to patients at diagnosis with active disease. The expression levels
of IL2 and IFNG were also decreased, but these alterations did not
reach statistical significance (Table 4). Interestingly, the alteration
of FOXP3 expression was not accompanied by a commensurate
decrease of CD4 mRNA levels.
The correlation of the expression between the analyzed genes,
the liver biochemistry [alanine aminotransferase (AST) and
aspartate aminotransferase (ALT) levels], and the viral load are
presented in detail in Figure 2.
The immunohistochemical staining for FOXP3,PD1,and PDL1
showed small numbers of positive lymphocytes in untreated liv-
ers, while positive cells practically disappeared following treatment
(Figure 3). Moreover, CD4+-lymphocytes were mostly located
in portal tracts, while CD8+-lymphocytes were found in por-
tal tracts, limiting plates, and lobules, in an extent commensu-
rate with their nature as effectors of necroinflammatory activity
(Figure 3).
GENE EXPRESSION IN RELATION TO THE INTENSITY OF
INFLAMMATION AND THE DEGREE OF FIBROSIS
In relation to the intensity of inflammation, FOXP3, PD1/PDCD1,
PDL1/PDCDLG1, and CD8a exhibited a statistically significant
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Table 2 | Primers and PCR conditions for the amplification of the analyzed genes.
Gene Primers Sequence PCR conditions
FOXP3 Forward Commercially obtained by Qiagen,
Cat No PPH00029B
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 60°C for 15 s,
72°C for 15 s)Reverse
IL10 Forward Commercially obtained by Qiagen,
Cat No PPH00572B
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 58°C for 60 s)
Reverse
TGFB1 Forward Commercially obtained by Qiagen,
Cat No PPH00508A
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 60°C for 60 s)
Reverse
FAS Forward Commercially obtained by Qiagen,
Cat No PPH00141B
95°C for 2 min, followed by 40 cycles (95°C for 10 s, 55°C for 10 s,
72°C for 20 s)Reverse
FASL Forward Commercially obtained by Qiagen,
Cat No PPH00142B
95°C for 2 min, followed by 40 cycles (95°C for 10 s, 55°C for 10 s,
72°C for 30 s)Reverse
TRAIL Forward Commercially obtained by Qiagen,
Cat No PPH00242E
95°C for 2 min, followed by 40 cycles (95°C for 10 s, 55°C for 10 s,
72°C for 20 s)Reverse
PD1 Forward Commercially obtained by Qiagen,
Cat No PPH13086E
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 60°C for 60 s)
Reverse
PDL1 Forward GGTGGTGCCGACTACAA 95°C for 2 min, followed by 40 cycles (95°C for 10 s, 58°C for 10 s,
72°C for 20 s)Reverse TAGCCCTCAGCCTGACAT
PDL2 Forward CTGTGGCAAGTCCTCATA 95°C for 2 min, followed by 40 cycles (95°C for 30 s, 55°C for 30 s,
72°C for 30 s)Reverse TAAAGCTGCTATCTGGTGA
IL2 Forward Commercially obtained by Qiagen,
Cat No PPH00172B
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 60°C for 60 s)
Reverse
TNFA Forward Commercially obtained by Qiagen,
Cat No PPH00341E
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 60°C for 60 s)
Reverse
IFNG Forward Commercially obtained by Qiagen,
Cat No PPH00380B
95°C for 10 min, followed by 40 cycles (95°C for 10 s, 58°C for 10 s,
72°C for 30 s)Reverse
CD4 Forward CATCAAGGTTCTGCCCACAT 95°C for 2 min, followed by 40 cycles (95°C for 10 s, 58°C for 10 s,
72°C for 20 s)Reverse TTCTAAACCGGTGAGGACAC
CD8a Forward GCTGGACTTCGCCTGTGATA 95°C for 2 min, followed by 40 cycles (95°C for 10 s, 55°C for 10 s,
72°C for 60 s)Reverse TGTCTCCCGATTTGACCAC
B2M Forward Commercially obtained by Qiagen,
Cat No PPH01094E
95°C for 10 min, followed by 40 cycles (95°C for 15 s, 60°C for 60 s)
Reverse
Table 3 | Antibodies and dilutions used in the present
immunohistochemical study.
Antigen Antibody
(clone)
Dilution Manufacturer
FOXP3 ab22510 1:50 Abcam (Cambridge, UK)
PD1 ab52587 1:25 Abcam (Cambridge, UK)
PDL1 (CD274) 29E.2A3 1:30 Biolegend (Athens, Greece)
CD4 NCL-L-CD4-1F6 1:20 Novocastra (Athens, Greece)
CD8 C8/144B 1:50 DAKO (Athens, Greece)
increase of expression from minimal to marked inflamma-
tion (Figure 4). This pattern of expression was nearly similar
for TNFSF6/FASL, although not reaching statistical significance
(p= 0.128). On the other hand, TNFSF10/TRAIL displayed an
opposite pattern of expression, decreasing from minimal to severe
inflammation (Figure 4). The expression of the other analyzed
genes was not affected by inflammation intensity (p> 0.05, in all
cases).
The severity of fibrosis was significantly associated only
with the expression of PDL1/PDCDLG1. A similar pattern
was observed for FOXP3 and PD1/PDCD1, and an oppo-
site one for TNFSF10/TRAIL, although not reaching sta-
tistical significance (p= 0.105, p= 0.080, p= 0.060, respec-
tively). The expression of the other analyzed genes was
not affected by the severity of fibrosis (p> 0.05, in all
cases).
Finally, as expected, HAI score was positively correlated with
the fibrosis stage (p< 0.001, r= 0.665), while the viral load was
also positively correlated with both HAI score and fibrosis stage
(p< 0.001, r= 0.724, and p= 0.003, r= 0.403, respectively).
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FIGURE 1 | Gene expressions with significant alteration of mRNA levels
in the liver of CHB patients. Error bar diagrams presenting the expression of
FOXP3 (A), PD1/PDCD1 (B), PDL1/PDCD1LG1 (C), CD8a (D), TGFB1 (E), IL10
(F), FASL (G), and TNFSF10/TRAIL (H) in the liver of patients in maintained
on-treatment long-term remission as compared to CHB patients at diagnosis.
The charts describe the algorithms for error bar computation of the mean±2
standard errors for the relative expression of each gene. p-Values in each
diagram refers to Mann–Whitney U test.
Table 4 | Relative expression of the examined genes with no statistical
significance between patients at diagnosis (n 30) and at remission
(n 23) of the disease.
No Gene CHB – diagnosis
(mean±SDEV)
CHB – remission
(mean±SDEV)
p-Value*
1 TNFRSF6/FAS 1.8±0.9 1.8±0.9 0.747
2 PDL2/PDCD1LG2 0.3±0.2 0.2±0.2 0.394
3 IL2 63.5±226.9 7.0±6.2 0.647
4 TNFA 35.9±100.1 22.7±36.7 0.342
5 IFNG 11.0±22.8 4.0±4.8 0.083
6 IL1B 0.6±1.4 0.1±0.1 0.083
7 CD4 0.7±1.1 0.5±0.5 0.628
CHB, chronic HBV hepatitis; SDEV, standard deviation.
*p-Values refer to Mann–Whitney U test.
DISCUSSION
Our study provides clear evidence that in the CHB HBeAg-
negative disease model, the expression of FOXP3, characterizing
mainly nTregs, as well as those of IL10 and TGFB1, characterizing
Tr1 and Th3 iTregs (6), are down-regulated in the liver in the main-
tained on-treatment long-term remission state, as compared with
cases histologically, biochemically, and virologically active at diag-
nosis, before any treatment. In addition, mRNA levels of liver FASL
and PD1 (mainly expressed by CTLs, characterized also by the
expression of CD8), and PDL1 (mainly attributed to infected hepa-
tocytes and infiltrating lymphocytes) are concomitantly down-
regulated in the maintained long-term remission state. How-
ever, the down-regulation of CD8, with no up-regulation of IL-2
(encoded by IL2) and IFN-γ (encoded by IFNG), is not in favor of
restoration of T cell immune-responsiveness, but rather indicates
reduction of CTLs and hepatocyte cytolysis when liver inflamma-
tion subsides on long-term antiviral treatment. These findings are
also supported by our immunohistochemical findings (Figure 3).
As mentioned above, the decrease of FOXP3 expression was not
followed by a commensurate decrease of CD4 mRNA levels in
human liver tissues. Obviously, this may reflect that not only Tregs
are CD4+ but also other T cell subtypes, such as Th17 cells (6).
However, a more specific analysis of T cell subpopulations by
FCM was not available in our human liver tissues, and this is
one of the limitations of our study. Consequently, the alterations
of the frequency of CD4+-T cells identified in our study could not
confidently be attributed to a specific T cell subpopulation.
Our data further support the notion that the PD1/PDL1 path-
way (elevated levels of PD1 on T cells and increased expression
of PDL1 on hepatocytes) is associated with T cell dysfunction in
chronic HBV and HCV infections (3). In this context, it has been
suggested that the disruption of this pathway is a logical therapeu-
tic strategy to rescue the dysfunctional T cells, aiming to restore
HBV/HCV-specific T cell responses. Fisicaro et al. (5) have also
reported in short term experimental ex vivo CHB models that the
functional recovery of HBV-specific T cells following PD1/PDL1
blockade was more pronounced for liver-resident T cells rather
than peripheral T cells, and was characterized by CD8+ cell pro-
liferation and the production of IFN-γ and IL-2 by intrahepatic
lymphocytes. However, it is still uncertain whether the expres-
sion of PDL1 on hepatocytes truly contributes to the development
of T cell exhaustion or if it is a homoeostatic mechanism that
dampens the inflammatory reaction (3). Kassel et al. reported
that the hepatic expression of PD1/PDL1 molecules links more
directly with the degree of inflammation than with the underlying
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FIGURE 2 | Correlation data of chronic HBV hepatitis patients. The dark gray shadow refers to correlation significance p<0.01 (two-tailed), while the light
gray shadow refers to correlation significance p<0.05 (two-tailed).
etiology of liver damage, concluding that the PD1 pathway may
assist the liver in protecting itself from immune-mediated destruc-
tion (22). Accordingly, our findings did not support an antiviral
Teffs function restoration in long-term maintained remission of
chronic HBV infection, since no significant differences of the
expression of CD4, IL2, and IFNG were observed. Interestingly,
the abovementioned findings, considering Teffs function at remis-
sion, are in line with the findings of Nan et al. suggesting that the
impaired immune responses of CHB patients are not fully restored
by therapy, since no significant differences in the expression of
IFN-gamma were found (23). On the other hand, the expressions
of PD1 and PDL1 were significantly associated with the intensity
of histological liver inflammation. Thus, we further support the
conclusions of Kassel et al. suggesting that the down-regulation of
PD1 and PDL1 molecules on maintained remission represents an
epiphenomenon, contributing to, or resulting from, the resolution
of an active liver inflammation.
Furthermore, we observed a down-regulation of the apoptosis
mediators FAS and FASL in the maintained long-term remission
state in CHB patients. Considering that previous studies, includ-
ing ours, have demonstrated that the contribution of Fas/FasL
pathway in CHB is of utmost importance, closely related to the
degree of liver inflammation (16, 24), our findings further con-
firm the notion that it represents the most common and efficient
pathway to kill virally infected cells in liver (25). On the other
hand, we unexpectedly observed an inverse correlation of TRAIL
expression with the intensity of liver inflammation and the disease
stage (active vs. remission), since patients on maintained remis-
sion displayed an up-regulation of its mRNA levels in liver. TRAIL
is a newly characterized TNF family member, triggering apoptosis
in various tumor and virus-infected cells, by binding to certain
death receptors, namely DR4 and DR5 (26–28). However, TRAIL
can also bind to the decoy receptors DcR1, neutralizing its down-
stream effect, and DcR2 causing activation of NFkappaB, leading
to transcription of genes known to antagonize the death-signaling
pathway and/or to promote inflammation (29, 30). As a result, the
increased levels of TRAIL are capable of not only inducing apop-
tosis but also reducing inflammation, as it has already been shown
in a rabbit knee model of inflammatory arthritis (31). Considering
that we have not investigated the activation cascades of TRAIL in
our disease model, further studies are required in order to shed
light on the precise role this protein plays in the pathogenesis
and/or restoration of liver inflammation.
Likewise, we observed a significant reduction of mRNA levels
of genes, which are indicative of T cell mediated immunosuppres-
sion, namely FOXP3, IL10, and TGFB1. Moreover, the expression
pattern of FOXP3 was identical with those observed by PD1 and
PDL1 genes, characterized by a significant positive correlation with
the intensity of liver inflammation (Figure 4). Although, Foxp3+-
Tregs seemed to protect the liver from immune damage and
compromise virus control during acute experimental HBV infec-
tion (5, 32), their role in chronic viral infections, both HBV and
HCV, has been shown to range from suppressing T cell responses
directed against viruses to down-regulating the immune responses
causing the liver damage (5). Thus, the initial expansion stage of
the adaptive immune response against viruses is followed by a con-
traction stage, during which Tregs might play a prominent role in
maintaining a delicate balance between a robust immune response
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FIGURE 3 | Immunohistochemical findings in liver biopsy specimens
from a patient with CHB with marked necroinflammatory activity and
a patient on maintained long-term remission. (A,B) FOXP3
immunopositivity in occasional lymphocytes; (C,D) CD8 antigen
immunopositivity in many lymphocytes located in portal tracts and hepatic
lobules before treatment, contrasted with rare positive lymphocytes after
treatment; (E,F) CD4 antigen immunopositivity in some lymphocytes
located in portal tracts; (G,H) PD1 immunopositivity in occasional
lymphocytes; (I,J) PDL1 immunopositivity in several lymphocytes.
to clear the infection and the immunopathological consequences
of sustained immune activation and inflammation (5).
Furthermore, recent data suggest that CD4+CD25+-Tregs play
an active role in CHB not only in modulating effectors of immune
response to HBV, but also in influencing the disease prognosis.
Several groups have reported that the frequency of Foxp3+-Tregs
in liver is significantly increased in patients with severe CHB
compared to healthy controls (1, 5, 10–14, 33, 34), while their fre-
quency in peripheral blood is significantly correlated with serum
viral load (13, 33). Interestingly, in such patients the depletion
of circulating Tregs led to an increase of IFN-γ production by
HBV-Ag-stimulated peripheral blood mononuclear cells (PBMC).
In addition, CD4+CD25+-Tregs were capable of suppressing the
proliferation of autologous PBMC mediated by HBV antigens,
probably reflecting the generation of HBV-Ag-specific tissue and
circulating Tregs (13). In this context, Stross et al. have recently
demonstrated that Tregs significantly delayed the clearance of
HBV from blood and infected hepatocytes in a mouse model of
acute HBV infection, by down-regulating antiviral activity of Teffs
through limiting cytokine production and cytotoxicity (32).
However, we recently observed that accumulation of Foxp3+-
Tregs takes place in patients with chronic liver inflammation
independently of the initial inducer of liver injury (toxic, autoim-
munity, and viral, including HBV infection), and it is correlated
with elevated expression of apoptosis mediators FAS, FASL, and
TRAIL (16). As a result, we have suggested a protective role of
Tregs expansion in chronic liver inflammation, in order to pre-
vent self-tissue damage and to avoid catastrophic pathology (16).
Should this be the case, the described suppression of virus-specific
T cells could be considered as a bystander effect of the nTregs
that have been expanded due to the persistent apoptosis-induced
inflammation. In favor to our hypothesis, Peiseler et al. have
recently reported the presence of normal frequencies and func-
tion of Tregs in patients with type 1 AIH; indeed, they found
higher Treg frequencies in blood and liver tissue during active
disease, correlated with the inflammatory activity of the liver, com-
pared with remission (35). Moreover, Otano et al. have recently
demonstrated an increase of hepatic Tregs accompanied by a sig-
nificantly high expression of anti-inflammatory cytokines, such
as TGF-β1 and IL-10, and immunosuppressive molecules, such as
PD1/PDL1, in WHV-chronically infected woodchucks (36). Thus,
similarly to chronic HBV infection, persistent WHV infection is
associated with a strong immunosuppressive environment within
the liver. We consider that the results presented herein, including
the study of PD1/PDL1 pathway, although correlative rather than
conclusive, further support the abovementioned proposed model.
As mentioned above, our CHB HBeAg-negative patients on
maintained on-treatment long-term remission displayed a down-
regulation of the hepatic expression of FOXP3, PD1, and PDL1 that
was also correlated with a minimal intensity of liver inflammation.
However, these patients did not exhibit immune restoration phe-
nomena, as they are evident in the ex vivo human HBV infection
(5, 37) and the animal models of acute (32) and chronic liver viral
infections (36). Therefore, the targeting of Tregs and/or PD1/PDL1
pathway in the acute, or the early chronic HBV infection set-
ting, should be carefully considered as a therapeutic strategy, since
their depletion may trigger autoimmune phenomena or increase
immune-mediated liver damage.
In conclusion, our data indicate that in the CHB HBeAg-
negative disease model, the immunosuppressive liver environment
is down-regulated in the maintained on-treatment long-term
remission state, as compared with cases histologically, biochemi-
cally, and virologically active at diagnosis, before any treatment. In
addition, the contraction of the inhibitory pathways, as measured
by the down-regulation of their liver mRNA expression in long-
term remission, is possibly a mere consequence of the diminution
of liver inflammation, after being hyper-expressed, in order to
counterbalance excessive allo- and/or auto-reactive Teffs clones.
ACKNOWLEDGMENTS
The authors would like to thank Dr K. Mantzoukis, Dr S.
Metallidis, and Dr. S. Anastasiadis, for collecting patients’ sam-
ples. This study has been co-financed by the European Union
www.frontiersin.org July 2013 | Volume 4 | Article 207 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Germanidis et al. FOXP3 in chronic HBV hepatitis
FIGURE 4 | Gene expressions in the liver of all CHB patients,
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for each patient cohort. p-Values in each diagram refers to Kruskal–Wallis H
test.
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